Publication | Open Access

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma

Without RituximabLymphoid NeoplasiaOncologyMetronomic TherapyPathologyAggressive Non-hodgkin LymphomaPharmacotherapyImmunotherapyMedicineRadiation OncologyChemotherapyCancer ResearchDose-adjusted Etoposide